Canopy Growth (CGC) Fundamentals 2026 — Revenue Analysis | SniperIQ
Canopy Growth (CGC) is a CA-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of
Canopy Growth (CGC) has a market capitalization of approximately
Canopy Growth's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 0.6x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
Canopy Growth runs a net profit margin of -84.8%, a gross margin of 22.2%, and an operating margin of -49.9%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
Canopy Growth reported revenue of CAD 285M for fiscal year 2026, with net income of -CAD 263M and earnings per share (EPS) of -0.88. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Canopy Growth does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Canopy Growth carries a debt-to-equity ratio of 0.40x and a current ratio of 3.34x, with a market beta of 2.42. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Canopy Growth (CGC) the key facts are: market cap
Get Canopy Growth's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.